Hims Weight Loss Side Effects: What GLP-1 Patients Report in 2026
Complete guide to Hims weight loss side effects in 2026. What GLP-1 patients experience on semaglutide and tirzepatide, management strategies, and how Trimi compares at $99/mo.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. Our team reviews GLP-1 side effect profiles across telehealth providers to help patients make informed treatment decisions.
Quick links: Semaglutide treatment, tirzepatide treatment, Hims vs Ro weight loss, and Hims promo code 2026.
More on GLP-1 Side Effects
Understanding Hims Weight Loss Side Effects
Hims weight loss side effects are among the most searched topics for patients considering GLP-1 medication through the Hims telehealth platform. Hims offers compounded semaglutide at $149 to $199 per month and compounded tirzepatide at varying price tiers, making it one of the higher-priced telehealth options for weight loss medication in 2026. Understanding what side effects to expect, how common they are, and how to manage them is essential before starting treatment on any platform.
The most important fact about Hims weight loss side effects is that they are driven by the medication, not the platform. Semaglutide and tirzepatide are GLP-1 receptor agonists that slow gastric emptying, reduce appetite, and affect how the body processes food. These mechanisms produce predictable gastrointestinal side effects — nausea, diarrhea, constipation, and vomiting — regardless of whether the medication is prescribed by Hims, Trimi, Ro, or any other provider.
Clinical trial data provides the most reliable picture of what patients experience. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults and found that semaglutide 2.4 mg produced 14.9 percent mean body weight loss over 68 weeks, with gastrointestinal events as the most frequently reported side effects. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) demonstrated that tirzepatide at the highest dose produced up to 22.5 percent body weight loss, with a similar gastrointestinal side effect profile. These results define what every patient on these medications can expect — the side effects are a feature of the drug class, not any individual provider.
The side effects described in this guide apply to all GLP-1 medications regardless of provider. Hims patients experience the same side effect profile as patients on Trimi, Ro, Found, or any other telehealth platform prescribing the same active ingredients.
Hims vs Trimi: Side Effects and Support Comparison
Because Hims and Trimi prescribe the same compounded GLP-1 medications from licensed 503B pharmacies, the side effect profiles are identical. What differs is pricing, provider support structure, and cost during the side effect management period.
| Factor | Hims | Trimi |
|---|---|---|
| Semaglutide Monthly Cost | $149 - $199/mo | $99/mo |
| Tirzepatide Monthly Cost | Varies by plan | $125/mo |
| GI Side Effects (Nausea) | 30 - 44% (medication-driven) | 30 - 44% (medication-driven) |
| GI Side Effects (Diarrhea) | 15 - 30% (medication-driven) | 15 - 30% (medication-driven) |
| Dose Titration Protocol | Gradual (standard) | Gradual (standard) |
| Provider Communication | Asynchronous messaging | Messaging + video |
| Dose Adjustment Support | Provider-initiated | Provider-initiated |
| Pause or Cancel | Available (check terms) | Available (no contract) |
| Annual Cost (Semaglutide) | $1,788 - $2,388 | $1,188 |
| Annual Savings vs Hims | — | $600 - $1,200 |
Common GLP-1 Side Effects: Clinical Trial Data
The following side effect data comes from the major clinical trials for semaglutide and tirzepatide. These rates apply to all patients using these medications, including those on the Hims platform. Understanding the frequency and typical duration helps patients set realistic expectations.
| Side Effect | Semaglutide (STEP trials) | Tirzepatide (SURMOUNT trials) | Severity | Typical Duration |
|---|---|---|---|---|
| Nausea | ~44% | 24 - 33% | Mild to moderate | 2 - 8 weeks |
| Diarrhea | ~30% | 18 - 25% | Mild to moderate | 1 - 4 weeks |
| Constipation | ~24% | 12 - 20% | Mild to moderate | Ongoing for some |
| Vomiting | ~24% | 8 - 15% | Mild to moderate | 1 - 4 weeks |
| Abdominal Pain | ~20% | 6 - 14% | Mild | 1 - 4 weeks |
| Headache | ~14% | 5 - 10% | Mild | 1 - 2 weeks |
| Fatigue | ~11% | 5 - 10% | Mild | 2 - 6 weeks |
| Dyspepsia | ~9% | 5 - 9% | Mild | 2 - 4 weeks |
| Injection Site Reaction | ~5% | ~5% | Mild | Minutes to hours |
Source: STEP 1 semaglutide trial (Wilding et al., NEJM, 2021) and SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM, 2022). Side effect percentages represent the proportion of patients who reported each event at any point during the trial, including mild or transient episodes. Discontinuation due to adverse events was below 7 percent in both trials.
Why GLP-1 Medications Cause Gastrointestinal Side Effects
Understanding why these side effects occur helps patients manage expectations and make informed decisions. GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking the natural hormone GLP-1, which plays a role in appetite regulation, insulin release, and gastric motility. The medication slows gastric emptying — the rate at which food leaves the stomach — which contributes to both the appetite-suppressing effect and the gastrointestinal side effects.
Nausea, the most commonly reported side effect, typically occurs because food stays in the stomach longer than usual. This delayed emptying can feel uncomfortable, especially when combined with eating habits that worked before starting medication but are now too much for the slowed digestive process. The good news is that the body generally adapts to this new pace of digestion within the first several weeks of each dose level.
Constipation occurs because the slowed transit time also affects the intestines, leading to harder and less frequent stools. Diarrhea, somewhat paradoxically, can occur because the body adjusts its fluid balance in the intestinal tract. Both typically resolve as the body adapts, though constipation can persist for some patients and may require dietary adjustments or over-the-counter remedies.
The dose titration schedule exists specifically to minimize these effects. By starting at a low dose and increasing gradually — typically every 4 weeks — the body has time to adjust at each level. Patients who escalate too quickly, skip doses and then restart, or who do not follow titration guidelines tend to experience more severe side effects. This is why working with a responsive provider who can adjust your titration schedule is important, regardless of whether you choose Hims or another platform.
Serious Side Effects: Rare but Important
While most Hims weight loss side effects are mild and temporary, GLP-1 medications carry warnings for rare but serious adverse events. These apply to all patients on semaglutide or tirzepatide regardless of provider.
Pancreatitis: Severe, persistent abdominal pain that radiates to the back, possibly with nausea and vomiting. Incidence is rare (less than 1 percent) but requires immediate medical attention. Stop the medication and seek emergency care.
Gallbladder disease: GLP-1 medications may increase the risk of gallstones, particularly during rapid weight loss. Symptoms include right upper abdominal pain, nausea, and fever. Report these to your provider promptly.
Thyroid C-cell tumors: Both semaglutide and tirzepatide carry a boxed warning about medullary thyroid carcinoma based on rodent studies. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.
Severe allergic reactions: Anaphylaxis, angioedema, or severe skin reactions are extremely rare but require emergency care. Symptoms include difficulty breathing, facial swelling, and widespread rash.
Kidney injury: Dehydration from persistent vomiting or diarrhea can stress the kidneys. Patients with pre-existing kidney conditions should be monitored closely. Stay hydrated and report decreased urination to your provider.
Hypoglycemia: Primarily a risk when GLP-1 medications are combined with insulin or sulfonylureas. Patients on combination therapy should monitor blood sugar closely.
How to Manage Hims Weight Loss Side Effects
These evidence-based management strategies apply to all GLP-1 patients. Whether you use Hims, Trimi, or another provider, these approaches are the most effective way to reduce side effect severity and improve day-to-day comfort during treatment.
Nausea Management
Eat smaller, more frequent meals throughout the day instead of two or three large meals
Avoid high-fat, greasy, or heavily spiced foods — these are the most common nausea triggers on GLP-1 medications
Try ginger tea, ginger chews, or ginger supplements — ginger has antiemetic properties supported by clinical evidence
Eat slowly and stop at the first sign of fullness — overeating past satiety is a primary nausea trigger
Stay well hydrated with small, frequent sips of water rather than large amounts at once
Constipation Management
Increase dietary fiber gradually through vegetables, fruits, and whole grains
Drink at least 64 ounces of water daily — dehydration worsens constipation significantly
Consider a fiber supplement like psyllium husk if dietary changes are insufficient
Maintain regular physical activity — even daily walking helps promote bowel regularity
Injection Timing and Technique
Inject at a consistent time each week to help your body adapt to a predictable schedule
Some patients find injecting in the evening or before bed reduces daytime nausea
Rotate injection sites between abdomen, thigh, and upper arm to minimize site reactions
Allow the medication to reach room temperature before injecting to reduce discomfort
For a deeper look at dietary strategies during GLP-1 treatment, see our guides on best foods for semaglutide and best foods for tirzepatide. For supplement guidance, see our best fiber supplements for GLP-1 guide.
When to Contact Your Provider
Most Hims weight loss side effects are manageable at home with the strategies above. However, certain symptoms require prompt medical attention. Contact your Hims provider, Trimi provider, or seek emergency care if you experience any of the following.
Persistent vomiting that prevents you from keeping down fluids for more than 24 hours
Severe abdominal pain that does not improve, especially pain radiating to the back (possible pancreatitis)
Signs of dehydration: dark urine, dizziness, rapid heartbeat, or significantly decreased urination
Right upper abdominal pain with fever or nausea (possible gallbladder issues)
Swelling of the face, tongue, or throat, or difficulty breathing (allergic reaction)
A lump or swelling in the neck, hoarseness, or difficulty swallowing (thyroid-related symptoms)
Severe diarrhea lasting more than 3 days that does not respond to dietary changes
Signs of hypoglycemia if you are also taking insulin or sulfonylureas: shakiness, confusion, sweating
If you experience a medical emergency, call 911 or go to your nearest emergency room. Do not wait for a telehealth response for severe symptoms. Both Hims and Trimi are telehealth platforms and are not equipped for emergency care.
Hims vs Trimi: Side Effect Support Compared
Since the medication side effects are identical between providers, the meaningful comparison is how each platform supports patients through the adjustment period. Here is how Hims and Trimi compare on the factors that matter most during side effect management.
| Support Factor | Hims | Trimi |
|---|---|---|
| Provider Access | Asynchronous messaging | Messaging + video consultations |
| Response Time | 24 - 48 hours typical | 24 hours typical |
| Dose Adjustment Process | Message provider for adjustment | Message or video for adjustment |
| Titration Flexibility | Provider-guided | Provider-guided |
| Medication Pause | Available (review terms) | Available (no contract) |
| Side Effect Guidance | Provider messaging | Provider messaging + resources |
| Semaglutide Cost | $149 - $199/mo | $99/mo |
| Tirzepatide Cost | Varies by plan | $125/mo |
| Cost During 3-Month Adjustment | $447 - $597 | $297 |
| 12-Month Total Cost (Semaglutide) | $1,788 - $2,388 | $1,188 |
The first 3 months of GLP-1 treatment are when most side effects occur and when provider support matters most. During this period, Hims patients pay $447 to $597 while Trimi patients pay $297 — a savings of $150 to $300 during the most critical adjustment window. For patients who need to slow their titration or temporarily pause treatment, lower monthly costs reduce the financial burden of an extended adjustment period.
If you are currently on Hims and considering a switch, see our guide on how to cancel Hims and switch providers for a step-by-step transition plan that prevents gaps in medication access.
Side Effects in Context: What the Clinical Data Shows
Side effects are a valid concern, but the clinical evidence shows that the vast majority of patients are able to continue treatment and achieve meaningful weight loss. Putting the side effect data in context helps patients make balanced decisions.
In the STEP 1 trial (Wilding et al., NEJM, 2021), 94.3 percent of semaglutide patients completed the treatment period. Only 7 percent discontinued due to adverse events — meaning 93 percent of patients who started treatment tolerated it well enough to continue. The patients who completed treatment achieved an average of 14.9 percent body weight loss, which is clinically significant for reducing cardiovascular risk, improving metabolic markers, and enhancing quality of life.
The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed even more striking results with tirzepatide. Patients on the highest dose (15 mg) achieved up to 22.5 percent body weight loss over 72 weeks. Discontinuation due to adverse events ranged from 4.3 to 7.1 percent across dose groups, again demonstrating that the overwhelming majority of patients tolerate the medication.
For patients weighing the side effect risk, the clinical takeaway is clear: most side effects are temporary and manageable, discontinuation rates are low, and the weight loss outcomes are substantial. Whether you access these medications through Hims or Trimi, the clinical benefit profile is the same — the difference is what you pay each month during treatment.
Bottom Line
Hims weight loss side effects are the same side effects experienced by every patient on semaglutide or tirzepatide, because the medication causes the effects — not the platform. Nausea, diarrhea, constipation, and vomiting are common during the first weeks of treatment but typically improve with proper management strategies and time. Serious side effects are rare, and clinical trial data shows that over 93 percent of patients tolerate GLP-1 medications well enough to continue treatment.
The meaningful difference between Hims and Trimi is cost. Hims charges $149 to $199 per month for compounded semaglutide. Trimi charges $99 per month for the same medication. Over 12 months, that is $600 to $1,200 in savings — money that stays in your pocket while you receive clinically equivalent treatment with equivalent side effect management support.
If you are experiencing side effects on Hims or any GLP-1 medication, do not stop your medication without consulting your provider. Use the management strategies in this guide, communicate with your provider about dose adjustments, and give your body time to adapt. The evidence strongly supports staying the course through the initial adjustment period.
Frequently Asked Questions
What are the most common Hims weight loss side effects?
The most common side effects reported by Hims weight loss patients are nausea (30 to 44 percent), diarrhea (15 to 30 percent), constipation (15 to 25 percent), vomiting (10 to 15 percent), and injection site reactions (5 to 10 percent). These rates come from clinical trial data for semaglutide and tirzepatide and are identical regardless of whether you get the medication from Hims, Trimi, or any other provider.
Are Hims side effects different from other GLP-1 providers?
No. GLP-1 side effects are caused by the medication itself, not the platform prescribing it. Whether you receive semaglutide from Hims at $149 to $199 per month or from Trimi at $99 per month, the side effect profile is the same because the active ingredient is identical. The difference between providers is how side effects are managed — provider responsiveness, dose titration protocols, and ongoing support.
How long do Hims weight loss side effects last?
Most GLP-1 side effects are worst during the first 4 to 8 weeks of treatment, especially during dose escalation. Nausea typically peaks in the first 2 weeks at each new dose and then improves. The STEP 1 trial found that the majority of gastrointestinal events were mild to moderate and transient. Fewer than 7 percent of participants discontinued due to side effects.
Can I reduce nausea on Hims weight loss medication?
Yes. Effective nausea management strategies include eating smaller and more frequent meals, avoiding high-fat or greasy foods, staying well hydrated, eating slowly, trying ginger tea or ginger supplements, and following the prescribed dose titration schedule. These approaches work regardless of your provider.
Does Hims offer support for managing side effects?
Hims provides asynchronous messaging with providers for side effect management. Response times vary. Trimi offers similar messaging-based provider access with the same dose adjustment capabilities at $99 per month for semaglutide — $50 to $100 less per month than Hims while providing equivalent clinical support.
Should I stop taking Hims weight loss medication if I have side effects?
Do not stop GLP-1 medication without consulting your provider. Most side effects are temporary and manageable. Your provider may recommend slowing the dose titration, adjusting the injection timing, or adding supportive treatments. Only discontinue if your provider advises it or if you experience severe symptoms like persistent vomiting, signs of pancreatitis, or severe allergic reactions.
Is Trimi better than Hims for managing side effects?
Both Hims and Trimi prescribe the same GLP-1 medications with the same side effect profiles. The clinical management approach is similar — gradual dose titration and provider-guided adjustments. The primary difference is cost: Trimi charges $99 per month for semaglutide versus Hims at $149 to $199, saving $600 to $1,200 annually. Lower cost means less financial pressure if you need to slow titration or pause treatment during the adjustment period.
Sources & References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. 14.9% mean body weight loss; GI adverse events most common.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. Up to 22.5% body weight loss; GI side effects most reported.
- FDA guidance on drug compounding: questions and answers regarding 503A and 503B compounding.
- FDA prescribing information for Wegovy (semaglutide) injection, including full adverse reactions profile.
- Hims & Hers Health telehealth platform and weight loss program pricing.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. Side effects can vary by individual. Trimi is a competitor to Hims — readers should be aware of our commercial perspective when evaluating comparisons.